The results of the ONWARDS 2 trial of insulin icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose, as ...

and biosimilars and Novo Nordisk's newer product Tresiba (insulin degludec), but is more suitable for people with fluctuating basal insulin needs, claims the group. That shorter half-life makes it ...